The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study

BACKGROUND: International guidelines, including NICE, recommend using the 21-gene Recurrence Score assay for guiding adjuvant treatment decisions in ER+, HER2-negative early breast cancer (BC). We investigated the impact of adding this assay to standard pathological tests on clinicians'/patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchel, Anna, Robinson, Tim, Comins, Charles, Shere, Mike, Varughese, Mohini, Sparrow, Geoff, Sahu, Ajay, Saunders, Louise, Bahl, Amit, Cawthorn, Simon J, Braybrooke, Jeremy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984867/
https://www.ncbi.nlm.nih.gov/pubmed/26954715
http://dx.doi.org/10.1038/bjc.2016.48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984867/
https://www.ncbi.nlm.nih.gov/pubmed/26954715
http://dx.doi.org/10.1038/bjc.2016.48

Ejemplares similares